Search by Drug Name or NDC
NDC 00088-2502-05 Apidra SoloStar 100 [iU]/mL Details
Apidra SoloStar 100 [iU]/mL
Apidra SoloStar is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by sanofi-aventis U.S. LLC. The primary component is INSULIN GLULISINE.
MedlinePlus Drug Summary
Insulin glulisine is used to treat type 1 diabetes (condition in which the body does not make insulin and therefore cannot control the amount of sugar in the blood). It is also used to treat people with type 2 diabetes (condition in which the blood sugar is too high because the body does not produce or use insulin normally) who need insulin to control their diabetes. In patients with type 1 diabetes, insulin glulisine is usually used with another type of insulin, unless it is used in an external insulin pump. In patients with type 2 diabetes, insulin glulisine also may be used with another type of insulin or with oral medication(s) for diabetes. Insulin glulisine is a short-acting, man-made version of human insulin. Insulin glulisine works by replacing the insulin that is normally produced by the body and by helping move sugar from the blood into other body tissues where it is used for energy. It also stops the liver from producing more sugar. Over time, people who have diabetes and high blood sugar can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems. Using medication(s), making lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking your blood sugar may help to manage your diabetes and improve your health. This therapy may also decrease your chances of having a heart attack, stroke, or other diabetes-related complications such as kidney failure, nerve damage (numb, cold legs or feet; decreased sexual ability in men and women), eye problems, including changes or loss of vision, or gum disease. Your doctor and other healthcare providers will talk to you about the best way to manage your diabetes.
Related Packages: 00088-2502-05Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Insulin Glulisine (rDNA origin) Injection
Product Information
NDC | 00088-2502 |
---|---|
Product ID | 0088-2502_3ad0d2f5-b5e2-4da9-8b4a-29ca1338eaad |
Associated GPIs | 2710400400D220 |
GCN Sequence Number | 060371 |
GCN Sequence Number Description | insulin glulisine INSULN PEN 100/ML SUBCUT |
HIC3 | C4G |
HIC3 Description | INSULINS |
GCN | 26508 |
HICL Sequence Number | 033152 |
HICL Sequence Number Description | INSULIN GLULISINE |
Brand/Generic | Brand |
Proprietary Name | Apidra SoloStar |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | insulin glulisine |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | INJECTION, SOLUTION |
Route | SUBCUTANEOUS |
Active Ingredient Strength | 100 |
Active Ingredient Units | [iU]/mL |
Substance Name | INSULIN GLULISINE |
Labeler Name | sanofi-aventis U.S. LLC |
Pharmaceutical Class | Insulin Analog [EPC], Insulin [Chemical/Ingredient] |
DEA Schedule | n/a |
Marketing Category | BLA |
Application Number | BLA021629 |
Listing Certified Through | 2024-12-31 |
Package
NDC 00088-2502-05 (00088250205)
NDC Package Code | 0088-2502-05 |
---|---|
Billing NDC | 00088250205 |
Package | 5 SYRINGE, PLASTIC in 1 CARTON (0088-2502-05) / 3 mL in 1 SYRINGE, PLASTIC (0088-2502-00) |
Marketing Start Date | 2009-02-24 |
NDC Exclude Flag | N |
Pricing Information | |
Price Per Unit | 10.5238 |
Pricing Unit | ML |
Effective Date | 2024-01-01 |
NDC Description | APIDRA SOLOSTAR 100 UNIT/ML |
Pharmacy Type Indicator | C/I |
OTC | N |
Explanation Code | 4, 5 |
Classification for Rate Setting | B |
As of Date | 2024-02-21 |